#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Treatments for Diabetic Foot Ulcers
1-1	0-2	4.	abstract[1]	new[1]	coref	8-5[81_1]
1-2	3-13	Treatments	abstract[1]	new[1]	_	_
1-3	14-17	for	abstract[1]	new[1]	_	_
1-4	18-26	Diabetic	abstract[1]|abstract|person[3]|abstract[4]	new[1]|new|new[3]|new[4]	coref|coref|coref	10-3|10-3|10-3
1-5	27-31	Foot	abstract[1]|person[3]|abstract[4]	new[1]|new[3]|new[4]	_	_
1-6	32-38	Ulcers	abstract[1]|abstract[4]	new[1]|new[4]	_	_

#Text=One strategy for the management of patients with a DFU is to introduce a multidisciplinary approach and address the multifactorial processes involved in DFUs .
2-1	39-42	One	abstract[5]	new[5]	_	_
2-2	43-51	strategy	abstract[5]	new[5]	_	_
2-3	52-55	for	abstract[5]	new[5]	_	_
2-4	56-59	the	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-5	60-70	management	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-6	71-73	of	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-7	74-82	patients	abstract[5]|abstract[6]|person[7]	new[5]|new[6]|new[7]	coref	3-65[32_7]
2-8	83-87	with	abstract[5]|abstract[6]|person[7]	new[5]|new[6]|new[7]	_	_
2-9	88-89	a	abstract[5]|abstract[6]|person[7]|abstract[8]	new[5]|new[6]|new[7]|new[8]	coref	12-13[95_8]
2-10	90-93	DFU	abstract[5]|abstract[6]|person[7]|abstract[8]	new[5]|new[6]|new[7]|new[8]	_	_
2-11	94-96	is	_	_	_	_
2-12	97-99	to	_	_	_	_
2-13	100-109	introduce	_	_	_	_
2-14	110-111	a	abstract[9]	new[9]	_	_
2-15	112-129	multidisciplinary	abstract[9]	new[9]	_	_
2-16	130-138	approach	abstract[9]	new[9]	_	_
2-17	139-142	and	_	_	_	_
2-18	143-150	address	_	_	_	_
2-19	151-154	the	abstract[10]	new[10]	_	_
2-20	155-169	multifactorial	abstract[10]	new[10]	_	_
2-21	170-179	processes	abstract[10]	new[10]	_	_
2-22	180-188	involved	_	_	_	_
2-23	189-191	in	_	_	_	_
2-24	192-196	DFUs	event	new	coref	3-44
2-25	197-198	.	_	_	_	_

#Text=The use of multi-disciplinary teams ( MDTs ) that include all relevant specialties ( i. e. , nursing , orthopedics , plastic surgery , vascular surgery , nutrition , and endocrinology departments ) has shown an effect of decreasing the risks associated with DFUs and amputation by 50 – 85 % , lowering costs , and leading to a better quality of life for patients with DFUs .
3-1	199-202	The	abstract[12]	new[12]	_	_
3-2	203-206	use	abstract[12]	new[12]	_	_
3-3	207-209	of	abstract[12]	new[12]	_	_
3-4	210-228	multi-disciplinary	abstract[12]|organization[13]	new[12]|new[13]	_	_
3-5	229-234	teams	abstract[12]|organization[13]	new[12]|new[13]	_	_
3-6	235-236	(	_	_	_	_
3-7	237-241	MDTs	abstract	new	_	_
3-8	242-243	)	_	_	_	_
3-9	244-248	that	_	_	_	_
3-10	249-256	include	_	_	_	_
3-11	257-260	all	event[15]	new[15]	appos	3-18[0_15]
3-12	261-269	relevant	event[15]	new[15]	_	_
3-13	270-281	specialties	event[15]	new[15]	_	_
3-14	282-283	(	_	_	_	_
3-15	284-286	i.	_	_	_	_
3-16	287-289	e.	_	_	_	_
3-17	290-291	,	_	_	_	_
3-18	292-299	nursing	abstract	giv	appos	3-22[18_0]
3-19	300-301	,	_	_	_	_
3-20	302-313	orthopedics	_	_	_	_
3-21	314-315	,	_	_	_	_
3-22	316-323	plastic	substance|event[18]	new|giv[18]	appos|appos	3-25[19_18]|3-25[19_18]
3-23	324-331	surgery	event[18]	giv[18]	_	_
3-24	332-333	,	_	_	_	_
3-25	334-342	vascular	event[19]	giv[19]	_	_
3-26	343-350	surgery	event[19]	giv[19]	_	_
3-27	351-352	,	_	_	_	_
3-28	353-362	nutrition	abstract	new	_	_
3-29	363-364	,	_	_	_	_
3-30	365-368	and	_	_	_	_
3-31	369-382	endocrinology	abstract|organization[22]	new|new[22]	_	_
3-32	383-394	departments	organization[22]	new[22]	_	_
3-33	395-396	)	_	_	_	_
3-34	397-400	has	_	_	_	_
3-35	401-406	shown	_	_	_	_
3-36	407-409	an	abstract[23]	new[23]	coref	20-3[153_23]
3-37	410-416	effect	abstract[23]	new[23]	_	_
3-38	417-419	of	_	_	_	_
3-39	420-430	decreasing	_	_	_	_
3-40	431-434	the	abstract[24]	new[24]	_	_
3-41	435-440	risks	abstract[24]	new[24]	_	_
3-42	441-451	associated	_	_	_	_
3-43	452-456	with	_	_	_	_
3-44	457-461	DFUs	abstract	giv	coref	3-67
3-45	462-465	and	_	_	_	_
3-46	466-476	amputation	abstract[26]	new[26]	_	_
3-47	477-479	by	abstract[26]	new[26]	_	_
3-48	480-482	50	abstract[26]|quantity[28]	new[26]|new[28]	_	_
3-49	483-484	–	abstract[26]|quantity[28]	new[26]|new[28]	_	_
3-50	485-487	85	abstract[26]|quantity|quantity[28]	new[26]|new|new[28]	_	_
3-51	488-489	%	abstract[26]|quantity[28]	new[26]|new[28]	_	_
3-52	490-491	,	_	_	_	_
3-53	492-500	lowering	_	_	_	_
3-54	501-506	costs	abstract	new	_	_
3-55	507-508	,	_	_	_	_
3-56	509-512	and	_	_	_	_
3-57	513-520	leading	_	_	_	_
3-58	521-523	to	_	_	_	_
3-59	524-525	a	abstract[30]	new[30]	_	_
3-60	526-532	better	abstract[30]	new[30]	_	_
3-61	533-540	quality	abstract[30]	new[30]	_	_
3-62	541-543	of	abstract[30]	new[30]	_	_
3-63	544-548	life	abstract[30]|abstract	new[30]|new	_	_
3-64	549-552	for	abstract[30]	new[30]	_	_
3-65	553-561	patients	abstract[30]|person[32]	new[30]|giv[32]	coref	12-27[99_32]
3-66	562-566	with	abstract[30]|person[32]	new[30]|giv[32]	_	_
3-67	567-571	DFUs	abstract[30]|person[32]|abstract	new[30]|giv[32]|giv	coref	4-3
3-68	572-573	.	_	_	_	_

#Text=Management of DFUs requires the correct classification of stage and severity .
4-1	574-584	Management	abstract[34]	new[34]	coref	13-13[106_34]
4-2	585-587	of	abstract[34]	new[34]	_	_
4-3	588-592	DFUs	abstract[34]|abstract	new[34]|giv	coref	5-4
4-4	593-601	requires	_	_	_	_
4-5	602-605	the	abstract[36]	new[36]	_	_
4-6	606-613	correct	abstract[36]	new[36]	_	_
4-7	614-628	classification	abstract[36]	new[36]	_	_
4-8	629-631	of	abstract[36]	new[36]	_	_
4-9	632-637	stage	abstract[36]|abstract	new[36]|new	_	_
4-10	638-641	and	abstract[36]	new[36]	_	_
4-11	642-650	severity	abstract[36]|abstract	new[36]|new	_	_
4-12	651-652	.	_	_	_	_

#Text=Adequate care for DFUs should include a focus on DM control as well as on wound care , proper infection control , relieving pressure , and optimizing blood flow .
5-1	653-661	Adequate	abstract[39]	new[39]	_	_
5-2	662-666	care	abstract[39]	new[39]	_	_
5-3	667-670	for	abstract[39]	new[39]	_	_
5-4	671-675	DFUs	abstract[39]|event	new[39]|giv	coref	6-10
5-5	676-682	should	_	_	_	_
5-6	683-690	include	_	_	_	_
5-7	691-692	a	abstract[41]	new[41]	_	_
5-8	693-698	focus	abstract[41]	new[41]	_	_
5-9	699-701	on	abstract[41]	new[41]	_	_
5-10	702-704	DM	abstract[41]|person|abstract[43]	new[41]|new|new[43]	coref|coref	5-19[47_43]|5-19[47_43]
5-11	705-712	control	abstract[41]|abstract[43]	new[41]|new[43]	_	_
5-12	713-715	as	_	_	_	_
5-13	716-720	well	_	_	_	_
5-14	721-723	as	_	_	_	_
5-15	724-726	on	_	_	_	_
5-16	727-732	wound	abstract|abstract[45]	new|new[45]	coref|coref|coref|coref	6-1[50_45]|7-25|6-1[50_45]|7-25
5-17	733-737	care	abstract[45]	new[45]	_	_
5-18	738-739	,	_	_	_	_
5-19	740-746	proper	abstract[47]	giv[47]	coref	6-5[51_47]
5-20	747-756	infection	abstract|abstract[47]	new|giv[47]	coref	6-25
5-21	757-764	control	abstract[47]	giv[47]	_	_
5-22	765-766	,	_	_	_	_
5-23	767-776	relieving	_	_	_	_
5-24	777-785	pressure	abstract	new	coref	6-20
5-25	786-787	,	_	_	_	_
5-26	788-791	and	_	_	_	_
5-27	792-802	optimizing	_	_	_	_
5-28	803-808	blood	abstract[49]	new[49]	_	_
5-29	809-813	flow	abstract[49]	new[49]	_	_
5-30	814-815	.	_	_	_	_

#Text=The basic care for the control and treatment of DFUs is focused on the management of adequate perfusion , pressure mitigation , control of infection , and debridement .
6-1	816-819	The	abstract[50]	giv[50]	coref	18-34[0_50]
6-2	820-825	basic	abstract[50]	giv[50]	_	_
6-3	826-830	care	abstract[50]	giv[50]	_	_
6-4	831-834	for	abstract[50]	giv[50]	_	_
6-5	835-838	the	abstract[50]|abstract[51]	giv[50]|giv[51]	coref	6-23[58_51]
6-6	839-846	control	abstract[50]|abstract[51]	giv[50]|giv[51]	_	_
6-7	847-850	and	abstract[50]	giv[50]	_	_
6-8	851-860	treatment	abstract[50]|abstract[52]	giv[50]|new[52]	coref	17-1[122_52]
6-9	861-863	of	abstract[50]|abstract[52]	giv[50]|new[52]	_	_
6-10	864-868	DFUs	abstract[50]|abstract[52]|abstract	giv[50]|new[52]|giv	coref	7-10
6-11	869-871	is	_	_	_	_
6-12	872-879	focused	_	_	_	_
6-13	880-882	on	_	_	_	_
6-14	883-886	the	person[54]	new[54]	_	_
6-15	887-897	management	person[54]	new[54]	_	_
6-16	898-900	of	person[54]	new[54]	_	_
6-17	901-909	adequate	person[54]|substance[55]	new[54]|new[55]	_	_
6-18	910-919	perfusion	person[54]|substance[55]	new[54]|new[55]	_	_
6-19	920-921	,	person[54]	new[54]	_	_
6-20	922-930	pressure	person[54]|abstract|abstract[57]	new[54]|giv|new[57]	coref|coref	7-24|7-24
6-21	931-941	mitigation	person[54]|abstract[57]	new[54]|new[57]	_	_
6-22	942-943	,	person[54]	new[54]	_	_
6-23	944-951	control	person[54]|abstract[58]	new[54]|giv[58]	coref	13-1[102_58]
6-24	952-954	of	person[54]|abstract[58]	new[54]|giv[58]	_	_
6-25	955-964	infection	person[54]|abstract[58]|event	new[54]|giv[58]|giv	_	_
6-26	965-966	,	person[54]	new[54]	_	_
6-27	967-970	and	person[54]	new[54]	_	_
6-28	971-982	debridement	person[54]|abstract	new[54]|new	_	_
6-29	983-984	.	_	_	_	_

#Text=With technological advancement , other series of therapies for DFUs have been implemented , such as the development of skin substitutes , negative pressure wound therapy , hyperbaric oxygen , the creation of new wound dressings that include growth factors , and the use of tissues from bioengineering .
7-1	985-989	With	_	_	_	_
7-2	990-1003	technological	abstract[61]	new[61]	_	_
7-3	1004-1015	advancement	abstract[61]	new[61]	_	_
7-4	1016-1017	,	_	_	_	_
7-5	1018-1023	other	abstract[62]	new[62]	_	_
7-6	1024-1030	series	abstract[62]	new[62]	_	_
7-7	1031-1033	of	abstract[62]	new[62]	_	_
7-8	1034-1043	therapies	abstract[62]|abstract[63]	new[62]|new[63]	coref	27-1[208_63]
7-9	1044-1047	for	abstract[62]|abstract[63]	new[62]|new[63]	_	_
7-10	1048-1052	DFUs	abstract[62]|abstract[63]|abstract	new[62]|new[63]|giv	_	_
7-11	1053-1057	have	_	_	_	_
7-12	1058-1062	been	_	_	_	_
7-13	1063-1074	implemented	_	_	_	_
7-14	1075-1076	,	_	_	_	_
7-15	1077-1081	such	_	_	_	_
7-16	1082-1084	as	_	_	_	_
7-17	1085-1088	the	abstract[65]	new[65]	_	_
7-18	1089-1100	development	abstract[65]	new[65]	_	_
7-19	1101-1103	of	abstract[65]	new[65]	_	_
7-20	1104-1108	skin	abstract[65]|object|object[67]	new[65]|new|new[67]	_	_
7-21	1109-1120	substitutes	abstract[65]|object[67]	new[65]|new[67]	_	_
7-22	1121-1122	,	abstract[65]	new[65]	_	_
7-23	1123-1131	negative	abstract[65]|abstract[70]	new[65]|new[70]	coref	18-1[132_70]
7-24	1132-1140	pressure	abstract[65]|abstract|abstract[70]	new[65]|giv|new[70]	_	_
7-25	1141-1146	wound	abstract[65]|abstract|abstract[70]	new[65]|giv|new[70]	coref	7-35
7-26	1147-1154	therapy	abstract[65]|abstract[70]	new[65]|new[70]	_	_
7-27	1155-1156	,	abstract[65]	new[65]	_	_
7-28	1157-1167	hyperbaric	abstract[65]|substance[71]	new[65]|new[71]	_	_
7-29	1168-1174	oxygen	abstract[65]|substance[71]	new[65]|new[71]	_	_
7-30	1175-1176	,	_	_	_	_
7-31	1177-1180	the	abstract[72]	new[72]	_	_
7-32	1181-1189	creation	abstract[72]	new[72]	_	_
7-33	1190-1192	of	abstract[72]	new[72]	_	_
7-34	1193-1196	new	abstract[72]|object[74]	new[72]|new[74]	_	_
7-35	1197-1202	wound	abstract[72]|abstract|object[74]	new[72]|giv|new[74]	_	_
7-36	1203-1212	dressings	abstract[72]|object[74]	new[72]|new[74]	_	_
7-37	1213-1217	that	_	_	_	_
7-38	1218-1225	include	_	_	_	_
7-39	1226-1232	growth	abstract|abstract[76]	new|new[76]	coref|coref	27-7[210_76]|27-7[210_76]
7-40	1233-1240	factors	abstract[76]	new[76]	_	_
7-41	1241-1242	,	_	_	_	_
7-42	1243-1246	and	_	_	_	_
7-43	1247-1250	the	abstract[77]	new[77]	_	_
7-44	1251-1254	use	abstract[77]	new[77]	_	_
7-45	1255-1257	of	abstract[77]	new[77]	_	_
7-46	1258-1265	tissues	abstract[77]|substance[78]	new[77]|new[78]	_	_
7-47	1266-1270	from	abstract[77]|substance[78]	new[77]|new[78]	_	_
7-48	1271-1285	bioengineering	abstract[77]|substance[78]|person	new[77]|new[78]|new	_	_
7-49	1286-1287	.	_	_	_	_

#Text=In this way , treatments for DPN , PAD , and infections have provided encouraging results .
8-1	1288-1290	In	_	_	_	_
8-2	1291-1295	this	abstract[80]	new[80]	_	_
8-3	1296-1299	way	abstract[80]	new[80]	_	_
8-4	1300-1301	,	_	_	_	_
8-5	1302-1312	treatments	abstract[81]	giv[81]	coref	10-1[87_81]
8-6	1313-1316	for	abstract[81]	giv[81]	_	_
8-7	1317-1320	DPN	abstract[81]|abstract	giv[81]|new	coref	12-1
8-8	1321-1322	,	abstract[81]	giv[81]	_	_
8-9	1323-1326	PAD	abstract[81]|place	giv[81]|new	_	_
8-10	1327-1328	,	abstract[81]	giv[81]	_	_
8-11	1329-1332	and	abstract[81]	giv[81]	_	_
8-12	1333-1343	infections	abstract[81]|abstract	giv[81]|new	_	_
8-13	1344-1348	have	_	_	_	_
8-14	1349-1357	provided	_	_	_	_
8-15	1358-1369	encouraging	_	_	_	_
8-16	1370-1377	results	abstract	new	_	_
8-17	1378-1379	.	_	_	_	_

#Text=4.1 .
9-1	1380-1383	4.1	abstract	new	_	_
9-2	1384-1385	.	_	_	_	_

#Text=Treatments for Diabetic Peripheral
10-1	1386-1396	Treatments	abstract[87]	giv[87]	coref	17-23[125_87]
10-2	1397-1400	for	abstract[87]	giv[87]	_	_
10-3	1401-1409	Diabetic	abstract[87]|abstract|abstract[89]	giv[87]|giv|new[89]	_	_
10-4	1410-1420	Peripheral	abstract[87]|abstract[89]	giv[87]|new[89]	_	_

#Text=Neuropathy
11-1	1421-1431	Neuropathy	abstract	new	coref	15-9[113_0]

#Text=DPN is a factor that increases the risk of the appearance of a DFU , owing to the loss of sensation in the limb , making patients vulnerable to trauma .
12-1	1432-1435	DPN	abstract	giv	coref	12-3[92_0]
12-2	1436-1438	is	_	_	_	_
12-3	1439-1440	a	abstract[92]	giv[92]	coref	13-13[0_92]
12-4	1441-1447	factor	abstract[92]	giv[92]	_	_
12-5	1448-1452	that	_	_	_	_
12-6	1453-1462	increases	_	_	_	_
12-7	1463-1466	the	abstract[93]	new[93]	_	_
12-8	1467-1471	risk	abstract[93]	new[93]	_	_
12-9	1472-1474	of	abstract[93]	new[93]	_	_
12-10	1475-1478	the	abstract[93]|abstract[94]	new[93]|new[94]	_	_
12-11	1479-1489	appearance	abstract[93]|abstract[94]	new[93]|new[94]	_	_
12-12	1490-1492	of	abstract[93]|abstract[94]	new[93]|new[94]	_	_
12-13	1493-1494	a	abstract[93]|abstract[94]|event[95]	new[93]|new[94]|giv[95]	coref	32-69[256_95]
12-14	1495-1498	DFU	abstract[93]|abstract[94]|event[95]	new[93]|new[94]|giv[95]	_	_
12-15	1499-1500	,	_	_	_	_
12-16	1501-1506	owing	_	_	_	_
12-17	1507-1509	to	_	_	_	_
12-18	1510-1513	the	abstract[96]	new[96]	_	_
12-19	1514-1518	loss	abstract[96]	new[96]	_	_
12-20	1519-1521	of	abstract[96]	new[96]	_	_
12-21	1522-1531	sensation	abstract[96]|abstract[97]	new[96]|new[97]	_	_
12-22	1532-1534	in	abstract[96]|abstract[97]	new[96]|new[97]	_	_
12-23	1535-1538	the	abstract[96]|abstract[97]|object[98]	new[96]|new[97]|new[98]	_	_
12-24	1539-1543	limb	abstract[96]|abstract[97]|object[98]	new[96]|new[97]|new[98]	_	_
12-25	1544-1545	,	_	_	_	_
12-26	1546-1552	making	_	_	_	_
12-27	1553-1561	patients	person[99]	giv[99]	coref	15-12[114_99]
12-28	1562-1572	vulnerable	person[99]	giv[99]	_	_
12-29	1573-1575	to	_	_	_	_
12-30	1576-1582	trauma	event	new	_	_
12-31	1583-1584	.	_	_	_	_

#Text=Tight glycemic control is the primary step and a main feature of DPN management .
13-1	1585-1590	Tight	abstract[102]	giv[102]	coref	13-5[103_102]
13-2	1591-1599	glycemic	abstract|abstract[102]	new|giv[102]	_	_
13-3	1600-1607	control	abstract[102]	giv[102]	_	_
13-4	1608-1610	is	_	_	_	_
13-5	1611-1614	the	abstract[103]	giv[103]	_	_
13-6	1615-1622	primary	abstract[103]	giv[103]	_	_
13-7	1623-1627	step	abstract[103]	giv[103]	_	_
13-8	1628-1631	and	abstract[103]	giv[103]	_	_
13-9	1632-1633	a	abstract[103]|abstract[104]	giv[103]|new[104]	_	_
13-10	1634-1638	main	abstract[103]|abstract[104]	giv[103]|new[104]	_	_
13-11	1639-1646	feature	abstract[103]|abstract[104]	giv[103]|new[104]	_	_
13-12	1647-1649	of	abstract[103]|abstract[104]	giv[103]|new[104]	_	_
13-13	1650-1653	DPN	abstract[103]|abstract[104]|abstract|abstract[106]	giv[103]|new[104]|giv|giv[106]	coref|coref|coref|coref	15-14|19-21[151_106]|15-14|19-21[151_106]
13-14	1654-1664	management	abstract[103]|abstract[104]|abstract[106]	giv[103]|new[104]|giv[106]	_	_
13-15	1665-1666	.	_	_	_	_

#Text=Normoglycemia is more effectively restored by a pancreas transplant .
14-1	1667-1680	Normoglycemia	place	new	_	_
14-2	1681-1683	is	_	_	_	_
14-3	1684-1688	more	_	_	_	_
14-4	1689-1700	effectively	_	_	_	_
14-5	1701-1709	restored	_	_	_	_
14-6	1710-1712	by	_	_	_	_
14-7	1713-1714	a	event[109]	new[109]	coref	15-20[118_109]
14-8	1715-1723	pancreas	object|event[109]	new|new[109]	coref	15-21
14-9	1724-1734	transplant	event[109]	new[109]	_	_
14-10	1735-1736	.	_	_	_	_

#Text=Several studies have demonstrated improvement of motor and sensory neuropathy in patients with DPN after they were treated with a pancreas transplant .
15-1	1737-1744	Several	event[110]	new[110]	coref	21-8[157_110]
15-2	1745-1752	studies	event[110]	new[110]	_	_
15-3	1753-1757	have	_	_	_	_
15-4	1758-1770	demonstrated	_	_	_	_
15-5	1771-1782	improvement	abstract[111]	new[111]	coref	24-37[190_111]
15-6	1783-1785	of	abstract[111]	new[111]	_	_
15-7	1786-1791	motor	abstract[111]|object	new[111]|new	_	_
15-8	1792-1795	and	abstract[111]	new[111]	_	_
15-9	1796-1803	sensory	abstract[111]|abstract[113]	new[111]|giv[113]	coref	24-29[0_113]
15-10	1804-1814	neuropathy	abstract[111]|abstract[113]	new[111]|giv[113]	_	_
15-11	1815-1817	in	abstract[111]|abstract[113]	new[111]|giv[113]	_	_
15-12	1818-1826	patients	abstract[111]|abstract[113]|person[114]	new[111]|giv[113]|giv[114]	ana	15-16[0_114]
15-13	1827-1831	with	abstract[111]|abstract[113]|person[114]	new[111]|giv[113]|giv[114]	_	_
15-14	1832-1835	DPN	abstract[111]|abstract[113]|person[114]|abstract	new[111]|giv[113]|giv[114]|giv	coref	17-6[123_0]
15-15	1836-1841	after	_	_	_	_
15-16	1842-1846	they	person	giv	coref	32-4[238_0]
15-17	1847-1851	were	_	_	_	_
15-18	1852-1859	treated	_	_	_	_
15-19	1860-1864	with	_	_	_	_
15-20	1865-1866	a	event[118]	giv[118]	_	_
15-21	1867-1875	pancreas	object|event[118]	giv|giv[118]	_	_
15-22	1876-1886	transplant	event[118]	giv[118]	_	_
15-23	1887-1888	.	_	_	_	_

#Text=However , discrepancies exist in the time of response .
16-1	1889-1896	However	_	_	_	_
16-2	1897-1898	,	_	_	_	_
16-3	1899-1912	discrepancies	abstract	new	_	_
16-4	1913-1918	exist	_	_	_	_
16-5	1919-1921	in	_	_	_	_
16-6	1922-1925	the	abstract[120]	new[120]	_	_
16-7	1926-1930	time	abstract[120]	new[120]	_	_
16-8	1931-1933	of	abstract[120]	new[120]	_	_
16-9	1934-1942	response	abstract[120]|event	new[120]|new	_	_
16-10	1943-1944	.	_	_	_	_

#Text=Pharmacological treatment is used for painful DPN manifested as numbness , burning , stabbing , or excruciating or intractable pain ; only three treatments are approved by the U.S. Food and Drug Administration for the pain associated with DPN , namely , pregabalin , tapentadol , and duloxetine .
17-1	1945-1960	Pharmacological	abstract[122]	giv[122]	coref	25-6[198_122]
17-2	1961-1970	treatment	abstract[122]	giv[122]	_	_
17-3	1971-1973	is	_	_	_	_
17-4	1974-1978	used	_	_	_	_
17-5	1979-1982	for	_	_	_	_
17-6	1983-1990	painful	abstract[123]	giv[123]	coref	17-39[0_123]
17-7	1991-1994	DPN	abstract[123]	giv[123]	_	_
17-8	1995-2005	manifested	_	_	_	_
17-9	2006-2008	as	_	_	_	_
17-10	2009-2017	numbness	_	_	_	_
17-11	2018-2019	,	_	_	_	_
17-12	2020-2027	burning	_	_	_	_
17-13	2028-2029	,	_	_	_	_
17-14	2030-2038	stabbing	_	_	_	_
17-15	2039-2040	,	_	_	_	_
17-16	2041-2043	or	_	_	_	_
17-17	2044-2056	excruciating	_	_	_	_
17-18	2057-2059	or	_	_	_	_
17-19	2060-2071	intractable	abstract[124]	new[124]	coref	17-35[127_124]
17-20	2072-2076	pain	abstract[124]	new[124]	_	_
17-21	2077-2078	;	_	_	_	_
17-22	2079-2083	only	_	_	_	_
17-23	2084-2089	three	abstract[125]	giv[125]	coref	26-3[0_125]
17-24	2090-2100	treatments	abstract[125]	giv[125]	_	_
17-25	2101-2104	are	_	_	_	_
17-26	2105-2113	approved	_	_	_	_
17-27	2114-2116	by	_	_	_	_
17-28	2117-2120	the	object[126]	new[126]	_	_
17-29	2121-2125	U.S.	object[126]	new[126]	_	_
17-30	2126-2130	Food	object[126]	new[126]	_	_
17-31	2131-2134	and	_	_	_	_
17-32	2135-2139	Drug	_	_	_	_
17-33	2140-2154	Administration	_	_	_	_
17-34	2155-2158	for	_	_	_	_
17-35	2159-2162	the	abstract[127]	giv[127]	coref	19-22[0_127]
17-36	2163-2167	pain	abstract[127]	giv[127]	_	_
17-37	2168-2178	associated	_	_	_	_
17-38	2179-2183	with	_	_	_	_
17-39	2184-2187	DPN	abstract	giv	coref	22-16
17-40	2188-2189	,	_	_	_	_
17-41	2190-2196	namely	substance[129]	new[129]	_	_
17-42	2197-2198	,	substance[129]	new[129]	_	_
17-43	2199-2209	pregabalin	substance[129]	new[129]	_	_
17-44	2210-2211	,	_	_	_	_
17-45	2212-2222	tapentadol	substance	new	_	_
17-46	2223-2224	,	_	_	_	_
17-47	2225-2228	and	_	_	_	_
17-48	2229-2239	duloxetine	substance	new	_	_
17-49	2240-2241	.	_	_	_	_

#Text=Another pharmacological therapy includes analgesics , such as tramadol , acetaminophen , and some opioids such as oxycodone , which have constipation and nausea as side effects , and must be taken with care because they can be misused .
18-1	2242-2249	Another	abstract[132]	giv[132]	coref	28-9[215_132]
18-2	2250-2265	pharmacological	abstract[132]	giv[132]	_	_
18-3	2266-2273	therapy	abstract[132]	giv[132]	_	_
18-4	2274-2282	includes	_	_	_	_
18-5	2283-2293	analgesics	abstract[133]	new[133]	_	_
18-6	2294-2295	,	abstract[133]	new[133]	_	_
18-7	2296-2300	such	abstract[133]	new[133]	_	_
18-8	2301-2303	as	abstract[133]	new[133]	_	_
18-9	2304-2312	tramadol	abstract[133]|substance	new[133]|new	_	_
18-10	2313-2314	,	abstract[133]	new[133]	_	_
18-11	2315-2328	acetaminophen	abstract[133]|substance	new[133]|new	_	_
18-12	2329-2330	,	abstract[133]	new[133]	_	_
18-13	2331-2334	and	abstract[133]	new[133]	_	_
18-14	2335-2339	some	abstract[133]|substance[136]	new[133]|new[136]	_	_
18-15	2340-2347	opioids	abstract[133]|substance[136]	new[133]|new[136]	_	_
18-16	2348-2352	such	abstract[133]|substance[136]	new[133]|new[136]	_	_
18-17	2353-2355	as	abstract[133]|substance[136]	new[133]|new[136]	_	_
18-18	2356-2365	oxycodone	abstract[133]|substance[136]|substance	new[133]|new[136]|new	_	_
18-19	2366-2367	,	_	_	_	_
18-20	2368-2373	which	_	_	_	_
18-21	2374-2378	have	_	_	_	_
18-22	2379-2391	constipation	abstract|abstract[139]	new|new[139]	ana|ana	18-36[0_139]|18-36[0_139]
18-23	2392-2395	and	abstract[139]	new[139]	_	_
18-24	2396-2402	nausea	abstract[139]|abstract[140]	new[139]|new[140]	_	_
18-25	2403-2405	as	abstract[139]|abstract[140]	new[139]|new[140]	_	_
18-26	2406-2410	side	abstract[139]|abstract[140]|abstract	new[139]|new[140]|new	_	_
18-27	2411-2418	effects	abstract[139]|abstract[140]	new[139]|new[140]	_	_
18-28	2419-2420	,	_	_	_	_
18-29	2421-2424	and	_	_	_	_
18-30	2425-2429	must	_	_	_	_
18-31	2430-2432	be	_	_	_	_
18-32	2433-2438	taken	_	_	_	_
18-33	2439-2443	with	_	_	_	_
18-34	2444-2448	care	abstract	giv	_	_
18-35	2449-2456	because	_	_	_	_
18-36	2457-2461	they	abstract	giv	_	_
18-37	2462-2465	can	_	_	_	_
18-38	2466-2468	be	_	_	_	_
18-39	2469-2476	misused	_	_	_	_
18-40	2477-2478	.	_	_	_	_

#Text=Therapy with antidepressants such as amitriptyline , nortriptyline , and venlafaxine , among others , has shown an efficacy in neuropathic pain management .
19-1	2479-2486	Therapy	event[144]	new[144]	_	_
19-2	2487-2491	with	event[144]	new[144]	_	_
19-3	2492-2507	antidepressants	event[144]|substance[145]	new[144]|new[145]	_	_
19-4	2508-2512	such	event[144]|substance[145]	new[144]|new[145]	_	_
19-5	2513-2515	as	event[144]|substance[145]	new[144]|new[145]	_	_
19-6	2516-2529	amitriptyline	event[144]|substance[145]|substance	new[144]|new[145]|new	_	_
19-7	2530-2531	,	event[144]|substance[145]	new[144]|new[145]	_	_
19-8	2532-2545	nortriptyline	event[144]|substance[145]|substance	new[144]|new[145]|new	_	_
19-9	2546-2547	,	event[144]|substance[145]	new[144]|new[145]	_	_
19-10	2548-2551	and	event[144]|substance[145]	new[144]|new[145]	_	_
19-11	2552-2563	venlafaxine	event[144]|substance[145]|substance	new[144]|new[145]|new	_	_
19-12	2564-2565	,	_	_	_	_
19-13	2566-2571	among	_	_	_	_
19-14	2572-2578	others	_	_	_	_
19-15	2579-2580	,	_	_	_	_
19-16	2581-2584	has	_	_	_	_
19-17	2585-2590	shown	_	_	_	_
19-18	2591-2593	an	abstract[149]	new[149]	_	_
19-19	2594-2602	efficacy	abstract[149]	new[149]	_	_
19-20	2603-2605	in	abstract[149]	new[149]	_	_
19-21	2606-2617	neuropathic	abstract[149]|abstract[151]	new[149]|giv[151]	ana	20-1[0_151]
19-22	2618-2622	pain	abstract[149]|abstract|abstract[151]	new[149]|giv|giv[151]	_	_
19-23	2623-2633	management	abstract[149]|abstract[151]	new[149]|giv[151]	_	_
19-24	2634-2635	.	_	_	_	_

#Text=It has an effect on the recapture of noradrenaline and serotonin , as well as on muscarinic effects .
20-1	2636-2638	It	abstract	giv	_	_
20-2	2639-2642	has	_	_	_	_
20-3	2643-2645	an	abstract[153]	giv[153]	_	_
20-4	2646-2652	effect	abstract[153]	giv[153]	_	_
20-5	2653-2655	on	abstract[153]	giv[153]	_	_
20-6	2656-2659	the	abstract[153]|event[154]	giv[153]|new[154]	_	_
20-7	2660-2669	recapture	abstract[153]|event[154]	giv[153]|new[154]	_	_
20-8	2670-2672	of	abstract[153]|event[154]	giv[153]|new[154]	_	_
20-9	2673-2686	noradrenaline	abstract[153]|event[154]	giv[153]|new[154]	_	_
20-10	2687-2690	and	abstract[153]|event[154]	giv[153]|new[154]	_	_
20-11	2691-2700	serotonin	abstract[153]|event[154]|substance	giv[153]|new[154]|new	_	_
20-12	2701-2702	,	_	_	_	_
20-13	2703-2705	as	_	_	_	_
20-14	2706-2710	well	_	_	_	_
20-15	2711-2713	as	_	_	_	_
20-16	2714-2716	on	_	_	_	_
20-17	2717-2727	muscarinic	abstract[156]	new[156]	coref	23-11[173_156]
20-18	2728-2735	effects	abstract[156]	new[156]	_	_
20-19	2736-2737	.	_	_	_	_

#Text=In spite of this , there are limited studies evaluating these drugs because their doses in clinical trials are not entirely reproducible in clinical practice .
21-1	2738-2740	In	_	_	_	_
21-2	2741-2746	spite	_	_	_	_
21-3	2747-2749	of	_	_	_	_
21-4	2750-2754	this	_	_	_	_
21-5	2755-2756	,	_	_	_	_
21-6	2757-2762	there	_	_	_	_
21-7	2763-2766	are	_	_	_	_
21-8	2767-2774	limited	event[157]	giv[157]	_	_
21-9	2775-2782	studies	event[157]	giv[157]	_	_
21-10	2783-2793	evaluating	_	_	_	_
21-11	2794-2799	these	object[158]	new[158]	ana	21-14[0_158]
21-12	2800-2805	drugs	object[158]	new[158]	_	_
21-13	2806-2813	because	_	_	_	_
21-14	2814-2819	their	object|quantity[160]	giv|new[160]	coref|coref	28-12[216_160]|28-12[216_160]
21-15	2820-2825	doses	quantity[160]	new[160]	_	_
21-16	2826-2828	in	quantity[160]	new[160]	_	_
21-17	2829-2837	clinical	quantity[160]|abstract[161]	new[160]|new[161]	coref	23-1[171_161]
21-18	2838-2844	trials	quantity[160]|abstract[161]	new[160]|new[161]	_	_
21-19	2845-2848	are	_	_	_	_
21-20	2849-2852	not	_	_	_	_
21-21	2853-2861	entirely	_	_	_	_
21-22	2862-2874	reproducible	_	_	_	_
21-23	2875-2877	in	_	_	_	_
21-24	2878-2886	clinical	abstract[162]	new[162]	_	_
21-25	2887-2895	practice	abstract[162]	new[162]	_	_
21-26	2896-2897	.	_	_	_	_

#Text=Alpha-lipoic acid ( ALA ) has been suggested as a potential therapeutic agent in treating DPN ; its antioxidant capacity seems to delay or reverse damages to peripheral nerves .
22-1	2898-2910	Alpha-lipoic	substance[163]	new[163]	ana	22-18[0_163]
22-2	2911-2915	acid	substance[163]	new[163]	_	_
22-3	2916-2917	(	_	_	_	_
22-4	2918-2921	ALA	place	new	coref	23-14
22-5	2922-2923	)	_	_	_	_
22-6	2924-2927	has	_	_	_	_
22-7	2928-2932	been	_	_	_	_
22-8	2933-2942	suggested	_	_	_	_
22-9	2943-2945	as	_	_	_	_
22-10	2946-2947	a	_	_	_	_
22-11	2948-2957	potential	_	_	_	_
22-12	2958-2969	therapeutic	_	_	_	_
22-13	2970-2975	agent	_	_	_	_
22-14	2976-2978	in	_	_	_	_
22-15	2979-2987	treating	_	_	_	_
22-16	2988-2991	DPN	abstract	giv	coref	26-27
22-17	2992-2993	;	_	_	_	_
22-18	2994-2997	its	substance|abstract[168]	giv|new[168]	_	_
22-19	2998-3009	antioxidant	person|abstract[168]	new|new[168]	_	_
22-20	3010-3018	capacity	abstract[168]	new[168]	_	_
22-21	3019-3024	seems	_	_	_	_
22-22	3025-3027	to	_	_	_	_
22-23	3028-3033	delay	_	_	_	_
22-24	3034-3036	or	_	_	_	_
22-25	3037-3044	reverse	_	_	_	_
22-26	3045-3052	damages	abstract	new	_	_
22-27	3053-3055	to	_	_	_	_
22-28	3056-3066	peripheral	object[170]	new[170]	_	_
22-29	3067-3073	nerves	object[170]	new[170]	_	_
22-30	3074-3075	.	_	_	_	_

#Text=Several human randomized controlled trials ( RCTs ) have investigated the effects of ALA in the development of diabetic nephropathy .
23-1	3076-3083	Several	abstract[171]	giv[171]	_	_
23-2	3084-3089	human	abstract[171]	giv[171]	_	_
23-3	3090-3100	randomized	abstract[171]	giv[171]	_	_
23-4	3101-3111	controlled	abstract[171]	giv[171]	_	_
23-5	3112-3118	trials	abstract[171]	giv[171]	_	_
23-6	3119-3120	(	_	_	_	_
23-7	3121-3125	RCTs	event	new	coref	24-4[178_0]
23-8	3126-3127	)	_	_	_	_
23-9	3128-3132	have	_	_	_	_
23-10	3133-3145	investigated	_	_	_	_
23-11	3146-3149	the	abstract[173]	giv[173]	_	_
23-12	3150-3157	effects	abstract[173]	giv[173]	_	_
23-13	3158-3160	of	abstract[173]	giv[173]	_	_
23-14	3161-3164	ALA	abstract[173]|place	giv[173]|giv	ana	24-12
23-15	3165-3167	in	_	_	_	_
23-16	3168-3171	the	abstract[175]	new[175]	_	_
23-17	3172-3183	development	abstract[175]	new[175]	_	_
23-18	3184-3186	of	abstract[175]	new[175]	_	_
23-19	3187-3195	diabetic	abstract[175]|abstract[176]	new[175]|new[176]	_	_
23-20	3196-3207	nephropathy	abstract[175]|abstract[176]	new[175]|new[176]	_	_
23-21	3208-3209	.	_	_	_	_

#Text=A meta-analysis of four RCTs ( n = 653 ) showed that , compared with placebo , intravenous ALA ( 600 mg per day ) decreased symptoms of neuropathy when administered for three weeks , but symptom improvement with oral ALA ( >600 mg per day for 3 – 5 weeks ) was not clinically significant .
24-1	3210-3211	A	abstract[177]	new[177]	_	_
24-2	3212-3225	meta-analysis	abstract[177]	new[177]	_	_
24-3	3226-3228	of	abstract[177]	new[177]	_	_
24-4	3229-3233	four	abstract[177]|event[178]	new[177]|giv[178]	_	_
24-5	3234-3238	RCTs	abstract[177]|event[178]	new[177]|giv[178]	_	_
24-6	3239-3240	(	_	_	_	_
24-7	3241-3242	n	quantity	new	_	_
24-8	3243-3244	=	_	_	_	_
24-9	3245-3248	653	quantity	new	_	_
24-10	3249-3250	)	_	_	_	_
24-11	3251-3257	showed	_	_	_	_
24-12	3258-3262	that	place	giv	coref	24-18[183_0]
24-13	3263-3264	,	_	_	_	_
24-14	3265-3273	compared	_	_	_	_
24-15	3274-3278	with	_	_	_	_
24-16	3279-3286	placebo	substance	new	_	_
24-17	3287-3288	,	_	_	_	_
24-18	3289-3300	intravenous	place[183]	giv[183]	coref	24-40[191_183]
24-19	3301-3304	ALA	place[183]	giv[183]	_	_
24-20	3305-3306	(	_	_	_	_
24-21	3307-3310	600	quantity[184]	new[184]	coref	24-43[192_184]
24-22	3311-3313	mg	quantity[184]	new[184]	_	_
24-23	3314-3317	per	quantity[184]	new[184]	_	_
24-24	3318-3321	day	quantity[184]|time	new[184]|new	_	_
24-25	3322-3323	)	_	_	_	_
24-26	3324-3333	decreased	_	_	_	_
24-27	3334-3342	symptoms	abstract[186]	new[186]	_	_
24-28	3343-3345	of	abstract[186]	new[186]	_	_
24-29	3346-3356	neuropathy	abstract[186]|abstract	new[186]|giv	coref	27-25[213_0]
24-30	3357-3361	when	_	_	_	_
24-31	3362-3374	administered	_	_	_	_
24-32	3375-3378	for	_	_	_	_
24-33	3379-3384	three	time[188]	new[188]	coref	24-51[0_188]
24-34	3385-3390	weeks	time[188]	new[188]	_	_
24-35	3391-3392	,	_	_	_	_
24-36	3393-3396	but	_	_	_	_
24-37	3397-3404	symptom	abstract|abstract[190]	new|giv[190]	_	_
24-38	3405-3416	improvement	abstract[190]	giv[190]	_	_
24-39	3417-3421	with	abstract[190]	giv[190]	_	_
24-40	3422-3426	oral	abstract[190]|place[191]	giv[190]|giv[191]	_	_
24-41	3427-3430	ALA	abstract[190]|place[191]	giv[190]|giv[191]	_	_
24-42	3431-3432	(	_	_	_	_
24-43	3433-3437	>600	quantity[192]	giv[192]	_	_
24-44	3438-3440	mg	quantity[192]	giv[192]	_	_
24-45	3441-3444	per	quantity[192]	giv[192]	_	_
24-46	3445-3448	day	quantity[192]|time[193]	giv[192]|new[193]	_	_
24-47	3449-3452	for	quantity[192]|time[193]	giv[192]|new[193]	_	_
24-48	3453-3454	3	quantity[192]|time[193]|time[194]	giv[192]|new[193]|new[194]	_	_
24-49	3455-3456	–	quantity[192]|time[193]|time[194]	giv[192]|new[193]|new[194]	_	_
24-50	3457-3458	5	quantity[192]|time[193]|time[194]|quantity	giv[192]|new[193]|new[194]|new	_	_
24-51	3459-3464	weeks	quantity[192]|time[193]|time[194]|time	giv[192]|new[193]|new[194]|giv	_	_
24-52	3465-3466	)	_	_	_	_
24-53	3467-3470	was	_	_	_	_
24-54	3471-3474	not	_	_	_	_
24-55	3475-3485	clinically	_	_	_	_
24-56	3486-3497	significant	_	_	_	_
24-57	3498-3499	.	_	_	_	_

#Text=There is no evidence evaluating long-term treatment .
25-1	3500-3505	There	_	_	_	_
25-2	3506-3508	is	_	_	_	_
25-3	3509-3511	no	abstract[197]	new[197]	_	_
25-4	3512-3520	evidence	abstract[197]	new[197]	_	_
25-5	3521-3531	evaluating	_	_	_	_
25-6	3532-3541	long-term	abstract[198]	giv[198]	coref	29-8[224_198]
25-7	3542-3551	treatment	abstract[198]	giv[198]	_	_
25-8	3552-3553	.	_	_	_	_

#Text=Currently , treatments based on the use of mesenchymal stem cells ( MSC ) derived from adipose tissue have been considered as a potential treatment against DPN .
26-1	3554-3563	Currently	_	_	_	_
26-2	3564-3565	,	_	_	_	_
26-3	3566-3576	treatments	abstract	giv	coref	31-1[233_0]
26-4	3577-3582	based	_	_	_	_
26-5	3583-3585	on	_	_	_	_
26-6	3586-3589	the	abstract[200]	new[200]	_	_
26-7	3590-3593	use	abstract[200]	new[200]	_	_
26-8	3594-3596	of	abstract[200]	new[200]	_	_
26-9	3597-3608	mesenchymal	abstract[200]|animal|object[203]	new[200]|new|new[203]	appos|appos	26-13[0_203]|26-13[0_203]
26-10	3609-3613	stem	abstract[200]|plant|object[203]	new[200]|new|new[203]	_	_
26-11	3614-3619	cells	abstract[200]|object[203]	new[200]|new[203]	_	_
26-12	3620-3621	(	_	_	_	_
26-13	3622-3625	MSC	object	giv	_	_
26-14	3626-3627	)	_	_	_	_
26-15	3628-3635	derived	_	_	_	_
26-16	3636-3640	from	_	_	_	_
26-17	3641-3648	adipose	abstract|object[206]	new|new[206]	_	_
26-18	3649-3655	tissue	object[206]	new[206]	_	_
26-19	3656-3660	have	_	_	_	_
26-20	3661-3665	been	_	_	_	_
26-21	3666-3676	considered	_	_	_	_
26-22	3677-3679	as	_	_	_	_
26-23	3680-3681	a	_	_	_	_
26-24	3682-3691	potential	_	_	_	_
26-25	3692-3701	treatment	_	_	_	_
26-26	3702-3709	against	_	_	_	_
26-27	3710-3713	DPN	abstract	giv	coref	29-21
26-28	3714-3715	.	_	_	_	_

#Text=These therapies promote the production of pro-angiogenic , neuroprotective , and anti-inflammatory factors , which have a positive impact on the clinical manifestations of the disease .
27-1	3716-3721	These	abstract[208]	giv[208]	_	_
27-2	3722-3731	therapies	abstract[208]	giv[208]	_	_
27-3	3732-3739	promote	_	_	_	_
27-4	3740-3743	the	abstract[209]	new[209]	_	_
27-5	3744-3754	production	abstract[209]	new[209]	_	_
27-6	3755-3757	of	abstract[209]	new[209]	_	_
27-7	3758-3772	pro-angiogenic	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
27-8	3773-3774	,	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
27-9	3775-3790	neuroprotective	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
27-10	3791-3792	,	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
27-11	3793-3796	and	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
27-12	3797-3814	anti-inflammatory	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
27-13	3815-3822	factors	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
27-14	3823-3824	,	_	_	_	_
27-15	3825-3830	which	_	_	_	_
27-16	3831-3835	have	_	_	_	_
27-17	3836-3837	a	abstract[211]	new[211]	_	_
27-18	3838-3846	positive	abstract[211]	new[211]	_	_
27-19	3847-3853	impact	abstract[211]	new[211]	_	_
27-20	3854-3856	on	abstract[211]	new[211]	_	_
27-21	3857-3860	the	abstract[211]|abstract[212]	new[211]|new[212]	_	_
27-22	3861-3869	clinical	abstract[211]|abstract[212]	new[211]|new[212]	_	_
27-23	3870-3884	manifestations	abstract[211]|abstract[212]	new[211]|new[212]	_	_
27-24	3885-3887	of	abstract[211]|abstract[212]	new[211]|new[212]	_	_
27-25	3888-3891	the	abstract[211]|abstract[212]|abstract[213]	new[211]|new[212]|giv[213]	coref	31-3[235_213]
27-26	3892-3899	disease	abstract[211]|abstract[212]|abstract[213]	new[211]|new[212]|giv[213]	_	_
27-27	3900-3901	.	_	_	_	_

#Text=On the other hand , the use of biological therapy with low doses of IL-6 has been demonstrated to promote improvement of blood flow , decrease chronic inflammation , and regenerate peripheral nerve fibers .
28-1	3902-3904	On	_	_	_	_
28-2	3905-3908	the	_	_	_	_
28-3	3909-3914	other	_	_	_	_
28-4	3915-3919	hand	_	_	_	_
28-5	3920-3921	,	_	_	_	_
28-6	3922-3925	the	abstract[214]	new[214]	_	_
28-7	3926-3929	use	abstract[214]	new[214]	_	_
28-8	3930-3932	of	abstract[214]	new[214]	_	_
28-9	3933-3943	biological	abstract[214]|abstract[215]	new[214]|giv[215]	_	_
28-10	3944-3951	therapy	abstract[214]|abstract[215]	new[214]|giv[215]	_	_
28-11	3952-3956	with	abstract[214]	new[214]	_	_
28-12	3957-3960	low	abstract[214]|quantity[216]	new[214]|giv[216]	_	_
28-13	3961-3966	doses	abstract[214]|quantity[216]	new[214]|giv[216]	_	_
28-14	3967-3969	of	abstract[214]|quantity[216]	new[214]|giv[216]	_	_
28-15	3970-3974	IL-6	abstract[214]|quantity[216]|substance	new[214]|giv[216]|new	coref	29-3
28-16	3975-3978	has	_	_	_	_
28-17	3979-3983	been	_	_	_	_
28-18	3984-3996	demonstrated	_	_	_	_
28-19	3997-3999	to	_	_	_	_
28-20	4000-4007	promote	_	_	_	_
28-21	4008-4019	improvement	event[218]	new[218]	_	_
28-22	4020-4022	of	event[218]	new[218]	_	_
28-23	4023-4028	blood	event[218]|abstract[219]	new[218]|new[219]	coref	32-11[240_219]
28-24	4029-4033	flow	event[218]|abstract[219]	new[218]|new[219]	_	_
28-25	4034-4035	,	_	_	_	_
28-26	4036-4044	decrease	_	_	_	_
28-27	4045-4052	chronic	abstract[220]	new[220]	_	_
28-28	4053-4065	inflammation	abstract[220]	new[220]	_	_
28-29	4066-4067	,	_	_	_	_
28-30	4068-4071	and	_	_	_	_
28-31	4072-4082	regenerate	_	_	_	_
28-32	4083-4093	peripheral	object[222]	new[222]	_	_
28-33	4094-4099	nerve	abstract|object[222]	new|new[222]	coref	29-18
28-34	4100-4106	fibers	object[222]	new[222]	_	_
28-35	4107-4108	.	_	_	_	_

#Text=Accordingly , IL-6 may prove to be an effective treatment for the protection and/or restoration of peripheral nerve function in DPN ; see Table 1 .
29-1	4109-4120	Accordingly	_	_	_	_
29-2	4121-4122	,	_	_	_	_
29-3	4123-4127	IL-6	substance	giv	_	_
29-4	4128-4131	may	_	_	_	_
29-5	4132-4137	prove	_	_	_	_
29-6	4138-4140	to	_	_	_	_
29-7	4141-4143	be	_	_	_	_
29-8	4144-4146	an	abstract[224]	giv[224]	_	_
29-9	4147-4156	effective	abstract[224]	giv[224]	_	_
29-10	4157-4166	treatment	abstract[224]	giv[224]	_	_
29-11	4167-4170	for	abstract[224]	giv[224]	_	_
29-12	4171-4174	the	abstract[224]|abstract[225]	giv[224]|new[225]	_	_
29-13	4175-4185	protection	abstract[224]|abstract[225]	giv[224]|new[225]	_	_
29-14	4186-4192	and/or	abstract[224]|abstract[225]	giv[224]|new[225]	_	_
29-15	4193-4204	restoration	abstract[224]|abstract[225]|abstract[226]	giv[224]|new[225]|new[226]	_	_
29-16	4205-4207	of	abstract[224]|abstract[225]|abstract[226]	giv[224]|new[225]|new[226]	_	_
29-17	4208-4218	peripheral	abstract[224]|abstract[225]|abstract[226]|abstract[228]	giv[224]|new[225]|new[226]|new[228]	_	_
29-18	4219-4224	nerve	abstract[224]|abstract[225]|abstract[226]|abstract|abstract[228]	giv[224]|new[225]|new[226]|giv|new[228]	_	_
29-19	4225-4233	function	abstract[224]|abstract[225]|abstract[226]|abstract[228]	giv[224]|new[225]|new[226]|new[228]	_	_
29-20	4234-4236	in	abstract[224]|abstract[225]|abstract[226]|abstract[228]	giv[224]|new[225]|new[226]|new[228]	_	_
29-21	4237-4240	DPN	abstract[224]|abstract[225]|abstract[226]|abstract[228]|abstract	giv[224]|new[225]|new[226]|new[228]|giv	_	_
29-22	4241-4242	;	_	_	_	_
29-23	4243-4246	see	_	_	_	_
29-24	4247-4252	Table	abstract	new	_	_
29-25	4253-4254	1	quantity	new	_	_
29-26	4255-4256	.	_	_	_	_

#Text=4.2 .
30-1	4257-4260	4.2	abstract	new	_	_
30-2	4261-4262	.	_	_	_	_

#Text=Treatments for Peripheral Arterial Disease ( Ischemia )
31-1	4263-4273	Treatments	abstract[233]	giv[233]	_	_
31-2	4274-4277	for	abstract[233]	giv[233]	_	_
31-3	4278-4288	Peripheral	abstract[233]|abstract[235]	giv[233]|giv[235]	appos	31-7[0_235]
31-4	4289-4297	Arterial	abstract[233]|abstract|abstract[235]	giv[233]|new|giv[235]	_	_
31-5	4298-4305	Disease	abstract[233]|abstract[235]	giv[233]|giv[235]	_	_
31-6	4306-4307	(	_	_	_	_
31-7	4308-4316	Ischemia	abstract	giv	coref	32-1
31-8	4317-4318	)	_	_	_	_

#Text=Ischemia presenting in diabetic patients due to a reduction in blood flow that occurs in both small vessels ( microvascular , such as capillaries ) and large vessels ( macrovascular , such as arteries and veins ) , or due to a decrease of angiogenesis , can be treated through revascularization of at least one of the foot arteries to try to restore blood flow in patients with a DFU whose toe pressure is <30 mmHg or transcutaneous oxygen pressure ( TcPO2 ) <25 mmHg , as well as in those who have a DFU that does not heal with pressure on the ankle of <50 mmHg or ankle-brachial index ( ABI ) <0.5 .
32-1	4319-4327	Ischemia	abstract	giv	_	_
32-2	4328-4338	presenting	_	_	_	_
32-3	4339-4341	in	_	_	_	_
32-4	4342-4350	diabetic	person[238]	giv[238]	coref	32-67[255_238]
32-5	4351-4359	patients	person[238]	giv[238]	_	_
32-6	4360-4363	due	_	_	_	_
32-7	4364-4366	to	_	_	_	_
32-8	4367-4368	a	abstract[239]	new[239]	_	_
32-9	4369-4378	reduction	abstract[239]	new[239]	_	_
32-10	4379-4381	in	abstract[239]	new[239]	_	_
32-11	4382-4387	blood	abstract[239]|abstract[240]	new[239]|giv[240]	coref	32-64[254_240]
32-12	4388-4392	flow	abstract[239]|abstract[240]	new[239]|giv[240]	_	_
32-13	4393-4397	that	_	_	_	_
32-14	4398-4404	occurs	_	_	_	_
32-15	4405-4407	in	_	_	_	_
32-16	4408-4412	both	object[241]	new[241]	_	_
32-17	4413-4418	small	object[241]	new[241]	_	_
32-18	4419-4426	vessels	object[241]	new[241]	_	_
32-19	4427-4428	(	_	_	_	_
32-20	4429-4442	microvascular	abstract[242]	new[242]	_	_
32-21	4443-4444	,	abstract[242]	new[242]	_	_
32-22	4445-4449	such	abstract[242]	new[242]	_	_
32-23	4450-4452	as	abstract[242]	new[242]	_	_
32-24	4453-4464	capillaries	abstract[242]|object	new[242]|new	_	_
32-25	4465-4466	)	_	_	_	_
32-26	4467-4470	and	_	_	_	_
32-27	4471-4476	large	object[244]	new[244]	_	_
32-28	4477-4484	vessels	object[244]	new[244]	_	_
32-29	4485-4486	(	_	_	_	_
32-30	4487-4500	macrovascular	abstract[245]	new[245]	_	_
32-31	4501-4502	,	abstract[245]	new[245]	_	_
32-32	4503-4507	such	abstract[245]	new[245]	_	_
32-33	4508-4510	as	abstract[245]	new[245]	_	_
32-34	4511-4519	arteries	abstract[245]|object	new[245]|new	coref	32-57[253_0]
32-35	4520-4523	and	abstract[245]	new[245]	_	_
32-36	4524-4529	veins	abstract[245]|object	new[245]|new	_	_
32-37	4530-4531	)	_	_	_	_
32-38	4532-4533	,	_	_	_	_
32-39	4534-4536	or	_	_	_	_
32-40	4537-4540	due	_	_	_	_
32-41	4541-4543	to	_	_	_	_
32-42	4544-4545	a	abstract[248]	new[248]	_	_
32-43	4546-4554	decrease	abstract[248]	new[248]	_	_
32-44	4555-4557	of	abstract[248]	new[248]	_	_
32-45	4558-4570	angiogenesis	abstract[248]|abstract	new[248]|new	_	_
32-46	4571-4572	,	_	_	_	_
32-47	4573-4576	can	_	_	_	_
32-48	4577-4579	be	_	_	_	_
32-49	4580-4587	treated	_	_	_	_
32-50	4588-4595	through	_	_	_	_
32-51	4596-4613	revascularization	event[250]	new[250]	_	_
32-52	4614-4616	of	event[250]	new[250]	_	_
32-53	4617-4619	at	event[250]|object[251]	new[250]|new[251]	_	_
32-54	4620-4625	least	event[250]|object[251]	new[250]|new[251]	_	_
32-55	4626-4629	one	event[250]|object[251]	new[250]|new[251]	_	_
32-56	4630-4632	of	event[250]|object[251]	new[250]|new[251]	_	_
32-57	4633-4636	the	event[250]|object[251]|object[253]	new[250]|new[251]|giv[253]	_	_
32-58	4637-4641	foot	event[250]|object[251]|object|object[253]	new[250]|new[251]|new|giv[253]	_	_
32-59	4642-4650	arteries	event[250]|object[251]|object[253]	new[250]|new[251]|giv[253]	_	_
32-60	4651-4653	to	_	_	_	_
32-61	4654-4657	try	_	_	_	_
32-62	4658-4660	to	_	_	_	_
32-63	4661-4668	restore	_	_	_	_
32-64	4669-4674	blood	abstract[254]	giv[254]	_	_
32-65	4675-4679	flow	abstract[254]	giv[254]	_	_
32-66	4680-4682	in	_	_	_	_
32-67	4683-4691	patients	person[255]	giv[255]	_	_
32-68	4692-4696	with	person[255]	giv[255]	_	_
32-69	4697-4698	a	person[255]|abstract[256]	giv[255]|giv[256]	coref	32-94[264_256]
32-70	4699-4702	DFU	person[255]|abstract[256]	giv[255]|giv[256]	_	_
32-71	4703-4708	whose	person[255]|abstract[258]	giv[255]|new[258]	coref	32-75[259_258]
32-72	4709-4712	toe	person[255]|object|abstract[258]	giv[255]|new|new[258]	_	_
32-73	4713-4721	pressure	person[255]|abstract[258]	giv[255]|new[258]	_	_
32-74	4722-4724	is	person[255]	giv[255]	_	_
32-75	4725-4728	<30	person[255]|abstract[259]	giv[255]|giv[259]	coref	32-78[261_259]
32-76	4729-4733	mmHg	person[255]|abstract[259]	giv[255]|giv[259]	_	_
32-77	4734-4736	or	person[255]	giv[255]	_	_
32-78	4737-4751	transcutaneous	person[255]|abstract[261]	giv[255]|giv[261]	appos	32-82[0_261]
32-79	4752-4758	oxygen	person[255]|substance|abstract[261]	giv[255]|new|giv[261]	_	_
32-80	4759-4767	pressure	person[255]|abstract[261]	giv[255]|giv[261]	_	_
32-81	4768-4769	(	_	_	_	_
32-82	4770-4775	TcPO2	abstract	giv	coref	32-101[265_0]
32-83	4776-4777	)	_	_	_	_
32-84	4778-4781	<25	quantity[263]	new[263]	_	_
32-85	4782-4786	mmHg	quantity[263]	new[263]	_	_
32-86	4787-4788	,	quantity[263]	new[263]	_	_
32-87	4789-4791	as	quantity[263]	new[263]	_	_
32-88	4792-4796	well	quantity[263]	new[263]	_	_
32-89	4797-4799	as	quantity[263]	new[263]	_	_
32-90	4800-4802	in	quantity[263]	new[263]	_	_
32-91	4803-4808	those	quantity[263]	new[263]	_	_
32-92	4809-4812	who	_	_	_	_
32-93	4813-4817	have	_	_	_	_
32-94	4818-4819	a	abstract[264]	giv[264]	_	_
32-95	4820-4823	DFU	abstract[264]	giv[264]	_	_
32-96	4824-4828	that	_	_	_	_
32-97	4829-4833	does	_	_	_	_
32-98	4834-4837	not	_	_	_	_
32-99	4838-4842	heal	_	_	_	_
32-100	4843-4847	with	_	_	_	_
32-101	4848-4856	pressure	abstract[265]	giv[265]	_	_
32-102	4857-4859	on	abstract[265]	giv[265]	_	_
32-103	4860-4863	the	abstract[265]|object[266]	giv[265]|new[266]	_	_
32-104	4864-4869	ankle	abstract[265]|object[266]	giv[265]|new[266]	_	_
32-105	4870-4872	of	abstract[265]|object[266]	giv[265]|new[266]	_	_
32-106	4873-4876	<50	abstract[265]|object[266]	giv[265]|new[266]	_	_
32-107	4877-4881	mmHg	abstract[265]|object[266]	giv[265]|new[266]	_	_
32-108	4882-4884	or	abstract[265]|object[266]	giv[265]|new[266]	_	_
32-109	4885-4899	ankle-brachial	abstract[265]|object[266]|object[267]	giv[265]|new[266]|new[267]	_	_
32-110	4900-4905	index	abstract[265]|object[266]|object[267]	giv[265]|new[266]|new[267]	_	_
32-111	4906-4907	(	_	_	_	_
32-112	4908-4911	ABI	abstract	new	_	_
32-113	4912-4913	)	_	_	_	_
32-114	4914-4918	<0.5	abstract	new	_	_
32-115	4919-4920	.	_	_	_	_
